← Back to Search

Antivenom

1 for Scorpion Sting

Phase 2 & 3
Waitlist Available
Led By Leslie Boyer, M.D
Research Sponsored by Instituto Bioclon S.A. de C.V.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediately after treatment, 24 hrs and 14 days.
Awards & highlights

Study Summary

This treatment protocol will enable therapeutic use of Anascorp in the management of systemic manifestations of scorpion sting envenomation, in patients for whom antivenom would otherwise be unavailable. The working hypotheses are as follows: The investigational antivenom is safe as treatment of scorpion sting envenomation. The investigational antivenom is effective as treatment of scorpion sting envenomation.

Eligible Conditions
  • Scorpion Sting

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and after treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluate the adverse events profile of each patient
Secondary outcome measures
Resolution of systemic signs of scorpion envenomation

Side effects data

From 2007 Phase 2 trial • 12 Patients • NCT00868309
33%
pruritus
33%
hyperhidrosis
17%
dry skin
17%
paraesthesia
17%
Rash
17%
musculoskeletal discomfort
17%
axillary pain
17%
dermatitis contact
17%
Rectal Hemorrhage
17%
Chest discomfort
17%
fatigue
17%
headache
17%
insomnia
17%
hypoaesthesia
17%
anorexia
17%
genital pruritus female
17%
Chills
17%
ecchymosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Anavip Crotalinae (Pit Viper) Equine Immune F(ab)2 Antivenom
CroFab Crotalidae Polyvalent Immune Fab, Ovine Antivenom

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Patients who arrive to emergency room with scorpion sting envenomation will be evaluated according to inclusion/exclusion criteria. After informed consent has been signed they will be assigned to unique treatment arm with Anascorp.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Scorpion (centruroides) immune Fab2 antivenin (equine)
FDA approved

Find a Location

Who is running the clinical trial?

Instituto Bioclon S.A. de C.V.Lead Sponsor
12 Previous Clinical Trials
818 Total Patients Enrolled
University of ArizonaOTHER
516 Previous Clinical Trials
147,045 Total Patients Enrolled
Walter Garcia, M.DStudy ChairInstituto Bioclon S.A. de C.V.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation
2005. "Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00624078.
~71 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top